Cellebrite DI (CLBT) Operating Expenses (2020 - 2025)

Cellebrite DI (CLBT) has reported Operating Expenses for 6 consecutive years, with $88.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Operating Expenses rose 16.68% year-over-year to $88.3 million; the TTM figure through Dec 2025 stood at $334.0 million (up 18.57% YoY), while the FY2025 annual figure was $334.0 million, up 18.57% from the prior year.
• Operating Expenses came in at $88.3 million for Q4 2025 at Cellebrite DI, up from $86.7 million in the prior quarter.
• The five-year high for Operating Expenses was $88.3 million in Q4 2025, with the low at $40.7 million in Q1 2021.
• Average Operating Expenses over 5 years is $63.2 million, with a median of $58.9 million recorded in 2023.
• Across the five-year window, Operating Expenses surged 64.07% in 2021 and retreated 0.69% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $51.3 million in 2021, then advanced by 1.85% to $52.2 million in 2022, then increased by 20.85% to $63.1 million in 2023, then increased by 19.97% to $75.7 million in 2024, then grew by 16.68% to $88.3 million in 2025.
• According to Business Quant data, Operating Expenses over the past three periods registered $88.3 million, $86.7 million, and $81.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.